Glucotrack raises $5.5M in combined equity and convertible debt financing

Glucotrack, Inc.

$2.0M equity PIPE at $0.75/unit: each unit includes one share (or pre-funded warrant) and a 5-year warrant at $1.50.
$3.5M follow-on bridge convertible debt with 8% interest, 9-month maturity, and 22% original issue discount.
Conversion and warrant exercise require stockholder approval; conversion price is lower of Nasdaq minimum or 80% of VWAP.
Proceeds to strengthen balance sheet and provide growth capital for portfolio execution.
E.F. Hutton & Co. served as exclusive advisor to Lōkahi Therapeutics, a Glucotrack subsidiary.

item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.